Blood Tests for Tuberculosis are Unreliable According to WHO – Positive for Biomagnetics Urine Based Tuberculosis Test

SAN FRANCISCO--(BUSINESS WIRE)-- Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP - News) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced that the World Health Organization (“WHO”) on Sunday July 17, 2011 warned that the widely used blood tests to detect tuberculosis (“TB”) are unreliable and “dangerous” to patients because they produce too many false negatives and positives.

WHO further recommended that doctors should not rely on these blood based TB tests. Mario Raviglione, the Director of WHO’s Stop TB Department, stated, “The tests are not reliable and a waste of money and time, putting proper care at risk.”

Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. commented, “This is the first time WHO has issued a “negative” policy in regards to the use of a particular method for diagnosing a disease. We are excited about the opportunity we have with our urine based assay, which has been developed by Los Alamos National Laboratory on behalf of Biomagnetics. TB testing is a large market opportunity for us. Currently around 14 million people worldwide have active TB and a third of the world’s population is believed to harbor the bacteria that causes TB.”

About Biomagnetics Diagnostics Corp.

Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company. The Company has developed a waveguide-based advanced integrated optical biosensor through its cooperative research and development agreement with Los Alamos National Security, LLC, which will initially be used for cholera and tuberculosis diagnosis. More information on Biomagnetics Diagnostics Corp. can be seen at www.biomagneticsbmgp.com.



CONTACT:

Investor Relations Contact:
Equiti-trend Advisors, LLC
800-953-3350

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Devices

MEDIA:

Logo
 Logo

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.